This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R.sup.1, R.sup.2, and R.sup.3 substituents are reported herein.

This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R.sup.1, R.sup.2, and R.sup.3 substituents are reported herein.

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.

Methods and compositions for preventing sympathetic activation resulting from administration of a TRPV1 modulator alone. Methods include co-administering QX-314 and a TRPV1 modulator to prevent sympathetic activation resulting from administration of a TRPV1 modulator alone comprising administering QX-314 and the TRPV1 modulator to a subject in need thereof. Compositions include a composition to prevent sympathetic activation comprising QX-314 and a TRPV1 modulator.

The present invention provides an edible composition for alleviating visual fatigue. The composition comprises in parts by weight 1 to 10 parts of curcuma powder, 1 to 12 parts of whole coffee fruit extract, 1 to 20 parts of phospholipid composite, 1 to 15 parts of DHA, 0.5 to 5 parts of phosphatidylserine, and 0.1 to 5 parts of vitamin C. After one week of trial consumption by the subject, the duration of photopic vision is improved with a significant difference in comparison with that before the trial; after 2 weeks of trial consumption, the overall score of visual fatigue symptoms decreases with a significant difference in comparison with that before the trial; after 8 weeks of trial consumption by the subject, the vision field thereof is remarkably enlarged, indicating the formulation may prevent the occurrence of glaucoma. The coffee extract combined with the remaining ingredients has a synergistic effect.

The present invention provides an edible composition for alleviating visual fatigue. The composition comprises in parts by weight 1 to 10 parts of curcuma powder, 1 to 12 parts of whole coffee fruit extract, 1 to 20 parts of phospholipid composite, 1 to 15 parts of DHA, 0.5 to 5 parts of phosphatidylserine, and 0.1 to 5 parts of vitamin C. After one week of trial consumption by the subject, the duration of photopic vision is improved with a significant difference in comparison with that before the trial; after 2 weeks of trial consumption, the overall score of visual fatigue symptoms decreases with a significant difference in comparison with that before the trial; after 8 weeks of trial consumption by the subject, the vision field thereof is remarkably enlarged, indicating the formulation may prevent the occurrence of glaucoma. The coffee extract combined with the remaining ingredients has a synergistic effect.

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

A sleep supplement composition that includes valerian extract, lemon balm extract, and L-theanine. In certain embodiments, the composition also includes melatonin.

A sleep supplement composition that includes valerian extract, lemon balm extract, and L-theanine. In certain embodiments, the composition also includes melatonin.